Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "EDB"

113 News Found

Abbott wins FDA & CE nod for groundbreaking premature infant heart device
Medical Device | December 22, 2025

Abbott wins FDA & CE nod for groundbreaking premature infant heart device

The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds


BPL Medical Technologies funds AI dept at Sri S Ramasamy Naidu Memorial College
News | December 21, 2025

BPL Medical Technologies funds AI dept at Sri S Ramasamy Naidu Memorial College

The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club


Exyte completes Pharmaplan integration
Biopharma | November 28, 2025

Exyte completes Pharmaplan integration

Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division


Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks
News | November 27, 2025

Medtronic launches first 'intelligent' circular stapler to boost surgical precision, reduce leaks

The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk


ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
Biopharma | November 16, 2025

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies


Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation
Digitisation | November 11, 2025

Mount Sinai to implement Microsoft Dragon Copilot for clinical documentation

Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly


Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026